| WELCOME TO THE LYMPHOMA FOUNDATION | ||||
Members of the Board and Friends
|
||||
|
EVENTS ON SUNDAY AFTERNOON APRIL 6, 2008 at the BETHPAGE STATE PARK TENNIS CENTER a successful charity Pro-Am tennis event was held that raised funds to support research grants to be distributed by the Lymphoma Foundation. The event was well attended and the tennis professionals David Fischbach and Keith Kambourian concluded the tennis event by hosting a bountiful buffet of various pasta dishes and deserts. Short presentations after the matches concluded were made recognizing the love and hope that David had for his mother, who is currently undergoing intense chemotherapy for lymphoma. David's remarks were deeply appreciated by the many family members and friends attending the event. David also gave special thanks to the Bethpage Park Tennis Center managers who set the courts aside for this special event. |
||||
|
Proceeds from the run will be supplemented by the Lymphoma Foundation to distribute grants for the support of basic lymphoma cell research, monoclonal anti-body research for non-Hodgkin's lymphoma and continuing clinical trials and improvements in stem cell transplantation for relapsing lymphoma |
||||
|
THE LACHER FELLOWS RESEARCH CONFERENCE OF THE MEMORIAL SLOAN
KETTERING CANCER CENTER WAS HELD ON WEDNESDAY
MORNING, JUNE 11, 2008 – IN THE ROCKEFELLER RESEARCH BUILDING The Conference was chaired by Dr. Craig Moskowitz, Clinical Director, Division of Hematologic Oncology and Dr. Mortimer J. Lacher provided concluding remarks |
||||
|
LYMPHOMA
FOUNDATION NEWS -
THE
LYMPHOMA FOUNDATION CONTINUES ITS GRANT SUPPORT OF RESEARCH
CONCERNING LEUKEMIA AND LYMPHOMA VACCINES AND
SEE BELOW: NEW PROTOCOLS BEING
ADVANCED FOR THE TREATMENT OF MULTIPLE MYELOMA
IMPORTANT NEW DATA : ABOUT YOUR VITAMIN D REQUIREMENT CONCERNING YOUR NEED FOR A HIGHER DAILY INTAKE OF VITAMIN D AND CAUTION WITH REGARD TO THE NEW SHINGLES (HERPES ZOSTER) VACCINE
JULY 2007 - DEVELOPING A CANCER VACCINE AGAINST LYMPHOMA —
IT IS ANTICIPATED THAT A PATIENT ORIENTED CLINICAL TRIAL OF THIS
CANCER VACCINE COULD BEGIN BEFORE THE END OF 2007 … (1) Guevara-Patino, J.A., M.E. Engelhorn, M.J. Turk, C. Liu, F. Duan, G. Rizzuto, A.D. Cohen, T. Merghoub, J.D. Wolchok, and A.N. Houghton. 2006. Optimization of a self antigen for presentation of multiple epitopes in cancer immunity. J Clin Invest 116:1382-1390. (2) Houghton, C.S., M.E. Engelhorn, C. Liu, D. Song, P. Gregor, P.O. Livingston, F. Orlandi, J.D. Wolchok, J. McCracken, A.N. Houghton, and J.A. Guevara-Patino. 2007. Immunological validation of the EpitOptimizer program for streamlined design of heteroclitic epitopes. Vaccine, in press.” PART II: JULY 2007 TO THE LYMPHOMA FOUNDATION: BY Maria Lia Palomba, MD and Alan N. Houghton, MD: Regarding a clinical trial of anti-CD20 DNA vaccine in patients with relapsed or refractory lymphoma: “We have developed a clinical trial for patients with relapsed or refractory lymphoma, and we are in the final stages of attaining approval to begin the trial, which we anticipate will be in the early fall 2007, pending no request to changes to the protocol:The protocol was approved by the Department of Medicine Steering Committee, Research Council and passed initial IRB review at MSKCC (along with several other committees). The protocol was approved by the Recombinant DNA Advisory Committee of the NIH after public review and following minor modifications. A pre-IND teleconference with the FDA raised only minor concerns. Toxicity studies in rabbits are now completed and show no evidence of toxic effects.The CD20 vaccine to be used in the proposed study has been manufactured and vialed, and the GMP-manufactured product is being stored at MSKCC in the Pharmacy Department and ready for use following protocol approval by the FDA. An IND application was recently submitted to the FDA. The protocol is also simultaneously undergoing final reviews by the MSKCC Institutional Biosafety Committee and the Institutional Review Board. Bringing this vaccine to clinical trials has been challenging but we are delighted to report that the clinical trial should begin in the next few months.” THE LACHER FELLOWS RESEARCH CONFERENCE 2007 - THE LACHER FELLOWS RESEARCH CONFERENCE WAS HELD AT THE MEMORIAL SLOAN KETTERING CANCER CENTER - THE ROCKEFELLER RESEARCH LABORATORY BUILDING on WEDNESDAY, JUNE 13, 2007 - 8:30AM to 11:30AM
Introduction: Tarun Kewalramani, M.D.
Justin Bekelman, M.D.
Mentor: Joachim Yahalom, M.D. and
Deborah Schrag, M.D.
Robert Jenq, M.D.
Mentor: Miguel Perales, M.D.
Alexander Lesokhin, M.D.
Mentor: Alan Houghton, M.D.
Matt Matasar, M.D., M.S.
Mentor: Andrew Zelenetz, M.D.
Concluding Remarks: Mortimer J.
Lacher, M.D. THE 10TH ANNUAL BRIAN ROONEY RUN/WALK IN CENTRAL PARK, NEW YORK CITY WAS HELD SATURDAY MORNING MAY 19, 2007 and once again the Run was attended by a wonderful group of 'runners' and 'walkers'. After the Run at Snapper Creek Tavern a delicious luncheon buffet was enjoyed by the participants Proceeds from the run will be supplemented by the Lymphoma Foundation to distribute grants for the support of basic lymphoma cell research, monoclonal anti-body research for non-Hodgkin's lymphoma and continuing clinical trials and improvements in stem cell transplantation for relapsing lymphoma |
||||
|
MULITPLE MYELOMA TREATMENT ENTERS A NEW PHASE:
IN AUGUST 2007 RAYMOND L. COMENZO, MD REPORTED TO
THE LYMPHOMA FOUNDATION: “Regarding
our current clinical research, we have three protocols open and
accruing that the Lymphoma Foundation is helping to support. The
first is a phase II trial that employs Bortezomib with multiple
other agents for patients with newly diagnosed high-risk multiple
myeloma. The second and third employ Bortezomib for patients with
systemic AL-amyloidosis. One is a phase II trial for newly diagnosed
patients who receive a stem cell transplant and then adjuvant
therapy with Bortezomib and dexamethasone if there is persistent
plasma cell disease. The other is a phase I/II trial for previously
treated patients with relapsed or progressive disease. This trial is
just entering the phase II level. Significant activity was seen
in the phase I portion of the study (25% complete response rate) as
reported at ASCO in June 2007. Clinical research in myeloma is
entering an era of more drugs and increasing complexity. At Memorial
Sloan Kettering Cancer Center our myeloma group is opening trials
for patients with advanced disease employing Bortezomib with 17-AAG
in one case and with Avastin in another. We are seeking approval for
a Bortezomib-based phase II trial as initial therapy in
non-transplant myeloma patients. We also have a phase II
investigator-initiated trial opening soon that uses the new agent
Lenalidomide (Revlimid) and Rituxan for CD20+ myeloma… “We depend
on the help of the Lymphoma Foundation and other supporters to allow
us to stay in the forefront of clinical research in myeloma asking
the hard question -- is early stem cell transplant better?
It is important to note that all the
investigator-initiated trials have translational objectives that are
laboratory-based. The Lymphoma Foundation's support is critical for
these efforts.” |
||||
|
NEW and NOTEWORTHY: About
the development of second cancers and heart disease after successful
lymphoma treatment... Women must do everything possible to try to detect the development of a second primary breast cancer at the earliest stage that may still be curable... by diligent attention to obtaining their mammograms (see data concerning the value of mammography). Second cancers induced primarily by a late effect of radiation is a continuing dilemma that is not easily solved. On the one hand radiation therapy can confer a long life free of the primary lymphoma and then, much later in life, it is the source of the development of a wide variety of second cancers that are still very difficult to treat. The death of a
young man from colon cancer 16 years after he was first treated for
Hodgkin's disease highlights this ongoing clinical
problem.
YOUR ATTENTION PLEASE... PRESERVING LONG LIFE BY ADDING A STATIN TO YOUR 'DIET' Ask your doctor to check your LDL-Cholesterol. It is more important than your total cholesterol. New data indicates that the 'old' guidelines may have to be revised and your goal should be an LDL-Cholesterol of 70 (seventy) or lower. For more information see the LYMPHOMA FOUNDATION NEWSLETTERS concerning recent Editorials about the value of statin medication, "THE IDEAL CHOLESTEROL: Lower is better" and the dilemma concerning the best treatment for Follicular Lymphomas and summaries of work in progress supported in part by Lymphoma Foundation grants. ALSO GO TO: UPDATE ON HEART and ARTERY CHANGES AFTER TREATMENT and review Commentary by Clinical and Basic Research Scientists receiving grant support from the Lymphoma Foundation to help you appreciate their efforts and accomplishments regarding vaccine therapy, monoclonal antibody treatments, the role of genetics in preventing or causing cancer, advances in the treatment of ovarian cancer, stem cell transplantation, radiation and chemotherapy to treat Hodgkin's disease, the non-Hodgkin's lymphomas, leukemia and myeloma and the unique role of the telomere in aging and cancer causation. THE LACHER FELLOWS RESEARCH CONFERENCE OF 2006 2006 - THE LACHER FELLOWS RESEARCH CONFERENCE WAS HELD AT THE MEMORIAL SLOAN KETTERING CANCER CENTER - THE ROCKEFELLER RESEARCH LABORATORY BUILDING on WEDNESDAY, JUNE 7, 2006
Introduction: Tarun
Kewalramani, M.D.
|
||||
    The runners got off to a good start while young Colin and Andrew Bresnahan wondered who would come in first... The first woman runner seemed to be flying toward the finish line leaving the pack far behind while some 'walkers' and their dog arrived in a more leisurely manner. Read more about the 2006 Rooney Run/Walk in Central Park |
||||
|
A note about our Board members: In 2004-2005 Ellen and Sandy Levin (from Texas), Deanne Spiegel (from Long Island, New York), Simone and Andrew McEntire (New York City), Andrew Bresnahan and Nancy Rooney (from Connecticut) joined the Board. In April, 2006 two distinguished clinician/scientists, lymphoma experts, Dr. Morton Coleman and Dr. John P. Leonard of the Lymphoma/Myeloma unit of the New York-Presbyterian Hospital, Cornell University Medical School also joined the Lymphoma Foundation Board. |
||||
|
INFORMATION FOR PERSONS WHO WANT TO LEARN ABOUT HUMAN RESEARCH CLINICAL TRIALS |
||||
|
Many individuals want to know where to find information concerning patient research trials: Just click on the ClinicalTrials.gov link and type in the subject you are looking for. For instance: When you reach the CLINICAL TRIALS website type in the words LYMPHOMA VACCINE and you will be directed to the current lymphoma vaccine trials. |
FOLLOW THIS LINK TO
HUMAN RESEARCH TRIALS You can also go to the Contact Page to be directed to additional links to useful sources of information |
|||
|
|
||||
| ATTENTION WOMEN SURVIVORS OF HODGKIN'S DISEASE |
LOWER YOUR CHOLESTEROL LEVELS
WITH STATIN MEDICATIONS:
CHECK OUT DATA
ON THE HEART PAGE
AND THE SEPTEMBER 2005 NEWSLETTER |
American Society of Hematology and American Society of Clinical
Oncology |
||
|
WHAT YOU SHOULD KNOW ABOUT BREAST CANCER
AND THE NEED FOR EARLY MAMMOGRAPHIC SURVEILLANCE
SUPPORT CANCER RESEARCH
MEMORIAL TRIBUTES |
ATTENTION
ALL PERSONS AND ESPECIALLY THOSE LYMPHOMA PATIENTS WHO RECEIVED RADIATION THERAPY THERE IS A WAY TO PREVENT CORONARY ARTERY DISEASE THAT LEADS TO HEART ATTACKS AND PREVENT BLOOD VESSEL DAMAGE FROM ATHEROSCLEROSIS... THAT MAY LEAD TO A STROKE BY LOWERING YOUR CHOLESTEROL LEVELS WITH STATIN MEDICATIONS: CHECK OUT THE DATA ON THE HEART PAGE SPECIAL HONORS
2006-2007
SPECIAL HONORS
- 2004 - 2005 |
DURING
2005-2006
LYMPHOMA
FOUNDATION RESEARCH GRANTS WERE AWARDED FOR: ►IMRT - INTENSITY MODULATED RADIATION THERAPY - Dr. Joachim Yahalom - MSKCC ►SPECIAL STUDY OF THE RELATIONSHIP OF RADIATION THERAPY TO BREAST CANCER - Dr. Joachim Yahalom - MSKCC
►RESEARCH OF AGING and NF1 --
NEUROFIBROMATOSIS -Dr. Christopher Counter - Duke University - Dr. Kenneth
Offit - and Dr. Suresh Jhanwar - Memorial Sloan Kettering Cancer Center
SPECIAL
JUNE
2007 MEETING
NATIONAL RESEARCH
MEETINGS |
||
|
||||
|
MISSION STATEMENT
OF THE LYMPHOMA FOUNDATION The Lymphoma Foundation is dedicated to the discovery of innovative and practical medical therapy by encouraging and supporting creative clinical and basic research scientists in their quest to find the cure for all lymphomas and cancer in general. GOALS OF THE LYMPHOMA FOUNDATION
|
||||
|
The Lymphoma Foundation supports outstanding
▲SCIENTISTS
who have contributed valuable academic and practical ▲RESEARCH as evidenced by their peer-reviewed ▼PUBLICATIONS. The
▲
BOARD
of the Lymphoma Foundation has also reached
out Through the Marie Project Initiative of the Lymphoma Foundation special efforts are supported that will lead to the prevention and cure of ▲BREAST CANCER ▲HEART DISEASE - AND THE IMPORTANCE of CONTROLLING YOUR CHOLESTEROL
▲EVENTS
and SCIENTIFIC MEETINGS |
||||
|
CALL THE LYMPHOMA FOUNDATION AT
|
||||
|
You can also write to the Lymphoma Foundation at the following address: The Lymphoma Foundation |
||||
|
▲SCIENTISTS ▲RESEARCH ▲ EVENTS ▲ BOARD ▲ FELLOWS ▲BREAST CANCER HEART DISEASE ▼PUBLICATIONS ▼CONTACT US
The Lymphoma Foundation is a nationwide not for profit foundation dedicated to funding clinical and basic laboratory cancer research and applying the knowledge developed by the clinician scientists to the general welfare and education of all cancer patients. © Copyright 2006 THE LYMPHOMA FOUNDATION All rights reserved |
||||
A special memorial note
about David Klein who succumbed to an uncontrollable colon cancer at
the age of 38, sixteen years after he was first treated for
Hodgkin's disease... may be found among the
SPECIAL MEMORIAL NOTICES on the 
The
Ninth Annual Lymphoma Foundation Brian Rooney Run/Walk was held on
Saturday May 20th, 2006 in Central Park, New York City and was
attended by an enthusiastic group of 'runners' and 'walkers'.
After the Run they all enjoyed a delicious luncheon buffet at
Snapper Creek. 
The
hand of tragedy reached out and ended a life of caring and generosity with
the sudden death of Edward Spiegel... another dedicated Board Member
of the Lymphoma Foundation ♥♥♥
